Markets:

Overview

News

Currencies

International

Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

6.320 +0.040 (+0.64%)

Streaming Delayed Price Updated: 3:33 PM EDT, May 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Recap: Xeris Biopharma Holdings Q4 Earnings ↗

March 10, 2022

Xeris Biopharma Holdings (NASDAQ:XERS) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the...

Via Benzinga

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

A Preview Of Xeris Pharmaceuticals's Earnings ↗

March 09, 2022

Xeris Pharmaceuticals (NASDAQ:XERS) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

Xeris Biopharma to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

February 09, 2022

From Xeris Biopharma Holdings

Via Business Wire

Xeris Biopharma Announces Recorlev® (levoketoconazole) Is Now Commercially Available for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

January 31, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

XERS Stock Pops on Huge FDA News. Here’s What to Know. ↗

December 31, 2021

The FDA approved Xeris' Recorlev drug for certain adult patients with Cushing's syndrome, sending XERS stock higher.

Via InvestorPlace

18 Stocks Moving in Monday's Pre-Market Session ↗

January 31, 2022

Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per...

Via Benzinga

Xeris Biopharma Eyes High End Of FY21 Sales Outlook ↗

January 18, 2022

Xeris Biopharma Holdings Inc (NASDAQ: XERS) has reaffirmed its preliminary 2021 pro forma sales at a high-end of $76 million - $80 million guidance, approximately...

Via Benzinga

Xeris Biopharma Reaffirms 2021 Guidance and Provides Business Update

January 18, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

PANTHERx Rare Selected By Xeris Pharmaceuticals To Distribute Recorlev ↗

January 13, 2022

PANTHERx Rare announces that it has been selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy...

Via Benzinga

Xeris Biopharma to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

January 06, 2022

From Xeris Biopharma

Via Business Wire

Xeris Biopharma Enters Into Agreement for $30 Million Private Placement

January 03, 2022

From Xeris Biopharma Holdings, Inc.

Via Business Wire

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

The Week Ahead In Biotech (Jan. 2-Jan. 8): Stray Clinical Readouts In Focus In Slow News Week ↗

January 02, 2022

Biotech stocks came under selling pressure in the final week of 2021, although they carved out modest gains for the year. Here are the key catalysts that can sway biotech stocks in the unfolding week.

Via Talk Markets

Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates ↗

December 31, 2021

Regulatory decisions by the U.S. Food and Drug Administration in December turned out to be mostly positive. Among the treatment options that were greenlighted in the month were...

Via Benzinga

Mid-Afternoon Market Update: Dow Rises 50 Points; Nutriband Shares Spike Higher ↗

December 31, 2021

Toward the end of trading Friday, the Dow traded up 0.14% to 36,449.17 while the NASDAQ fell 0.20% to 15,710.56. The S&P also rose, gaining 0.08% to 4,782.32. The U.S. has the...

Via Benzinga

What 4 Analyst Ratings Have To Say About Xeris Biopharma Holdings ↗

December 31, 2021

Analysts have provided the following ratings for Xeris Biopharma Holdings (NASDAQ:

Via Benzinga

Mid-Day Market Update: Crude Oil Down 1%; Xeris Biopharma Shares Jump ↗

December 31, 2021

Midway through trading Friday, the Dow traded down 0.08% to 36,370.19 while the NASDAQ fell 0.07% to 15,730.21. The S&P also fell, dropping 0.02% to 4,777.65. The U.S. has the...

Via Benzinga

21 Stocks Moving In Friday's Mid-Day Session ↗

December 31, 2021

Gainers Nutriband Inc. (NASDAQ: NTRB) shares jumped 120.2% to $8.61 after the company announced the Korean Intellectual Property Office has fully issued its patent titled "...

Via Benzinga

4 Biggest Price Target Changes For Friday ↗

December 31, 2021

SVB Leerink boosted the price target on Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) from $6 to $8. Xeris Biopharma shares rose 18.9% to $2.89 in pre-market trading....

Via Benzinga

Why Xeris Biopharma Shares Are Rising Today ↗

December 31, 2021

Xeris Biopharma Holdings Inc (NASDAQ: XERS) is trading higher Friday morning after the company announced U.S. Food and Drug Administration approval of Recorlev for the...

Via Benzinga

18 Stocks Moving in Friday's Pre-Market Session ↗

December 31, 2021

Gainers Medalist Diversified REIT, Inc. (NASDAQ: MDRR) rose 34.3% to $1.37 in pre-market trading after the company reported a stock repurchase program of 500,000 shares. Xeris...

Via Benzinga

A Peek Into The Markets: US Stock Futures Edge Lower On Final Trading Day Of 2021 ↗

December 31, 2021

Pre-open movers U.S. stock futures traded slightly lower in early pre-market trade on the final trading day of 2021. The Dow Jones dropped around 90 points, snapping a six-session...

Via Benzinga

5 Stocks To Watch For December 31, 2021 ↗

December 31, 2021

Some of the stocks that may grab investor focus today are: Medalist Diversified REIT, Inc. (NASDAQ: MDRR) reported a stock repurchase program of 500,000 shares. Medalist...

Via Benzinga

Xeris Biopharma Announces U.S. FDA Approval of Recorlev® (levoketoconazole) for the Treatment of Endogenous Hypercortisolemia in Adult Patients With Cushing’s Syndrome

December 30, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

5 Beaten Down Biotech Stocks That Could Bounce Big In 2022 ↗

December 27, 2021

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout...

Via Benzinga

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year ↗

December 26, 2021

Biopharma stocks eked out modest gains in the week ending Dec. 23, with regulatory decisions, clinical readouts and COVID-19 treatment and vaccine developments dictating...

Via Benzinga

Xeris Biopharma Announces the Availability of Ogluo® in the UK Through Its Commercialization Partner, Tetris Pharma

December 16, 2021

From Xeris Biopharma Holdings, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2021 ↗

November 17, 2021

Upgrades According to Williams Capital, the prior rating for On Holding AG (NYSE:

Via Benzinga

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.